Fractional Chief Financial Officer

This advanced manufacturing business in the Life Sciences sector is preparing for a near-term private equity transaction with EBITDA under £10 million. The company has strong commercial momentum and long-term customer relationships but needs significant finance function professionalisation to meet PE-grade standards.

The Fractional CFO will work 2-3 days per week, partnering closely with the CEO and external advisors to introduce financial rigour and transparency within this historically founder-led environment. This hands-on role combines strategic leadership with operational delivery, focusing on PE-quality financial information and ensuring full readiness for diligence processes.

• Partner with CEO to develop financial strategy aligned to growth, margin optimisation, and exit objectives
• Provide commercial insight across manufacturing operations, including product profitability and pricing strategy
• Lead financial readiness for private equity transaction, working with advisors throughout due diligence
• Build and embed KPIs covering revenue mix, gross margin, utilisation, and working capital management
• Own budgeting, forecasting, EBITDA normalisation, and cashflow modelling for transaction preparation
• Professionalise finance function through systems implementation and strengthened financial controls

• Experienced CFO or Fractional CFO with proven track record supporting PE-backed or PE-bound businesses
• Background in advanced manufacturing, engineered products, or Life Sciences supply chain strongly preferred
• Proven experience leading finance function professionalisation and reporting upgrades in growing SMEs
• Hands-on transaction experience, including sell-side PE processes and financial due diligence
• Strong commercial mindset with ability to partner founders, engineers, and non-finance stakeholders
• Comfortable operating in fast-scaling environments whilst building robust financial frameworks

Finatal operates in the advanced manufacturing sector serving the Life Sciences industry. It is a fast-growing business with EBITDA under £10 million, preparing for private equity investment with strong commercial momentum and differentiated manufacturing capabilities.